{"filing":{"accession_number":"0001628280-26-061174","cik":"0000834365","ticker":"BLFS","company_name":"BIOLIFE SOLUTIONS INC","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-03","primary_document":"blfs-20260903.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828026061174/blfs-20260903.htm"},"events":[{"id":32433,"run_id":29797,"accession_number":"0001628280-26-061174","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"BioLife Solutions disclosed a material acquisition by Repligen Corporation pursuant to an Agreement and Plan of Merger dated July 21, 2026. The disclosure details the merger structure (two-step merger with Merger Sub entities), the consideration ($11.25 cash plus 0.1442 Repligen shares per BioLife share), and key closing conditions including HSR approval (which expired September 3, 2026) and pending stockholder approval scheduled for October 5, 2026. This is a change-of-control transaction that materially affects BioLife's shareholders and is a core M\u0026A activity event.","company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35601,"accession_number":"0001628280-26-061174","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"BioLife Solutions disclosed a material acquisition by Repligen Corporation pursuant to an Agreement and Plan of Merger dated July 21, 2026. The disclosure details the merger structure (two-step merger with Merger Sub entities), the consideration ($11.25 cash plus 0.1442 Repligen shares per BioLife share), and key closing conditions including HSR approval (which expired September 3, 2026) and pending stockholder approval scheduled for October 5, 2026. This is a change-of-control transaction that materially affects BioLife's shareholders and is a core M\u0026A activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T21:22:42.062276+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35601,"accession_number":"0001628280-26-061174","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"BioLife Solutions disclosed a material acquisition by Repligen Corporation pursuant to an Agreement and Plan of Merger dated July 21, 2026. The disclosure details the merger structure (two-step merger with Merger Sub entities), the consideration ($11.25 cash plus 0.1442 Repligen shares per BioLife share), and key closing conditions including HSR approval (which expired September 3, 2026) and pending stockholder approval scheduled for October 5, 2026. This is a change-of-control transaction that materially affects BioLife's shareholders and is a core M\u0026A activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T21:22:42.062276+00:00","company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","filing_date":"2026-09-09"}]}